• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Definium Therapeutics, Inc. - Common Shares (NQ:DFTX)

36.90 +2.72 (+7.96%)
Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,773,835
Open 34.85
Bid (Size) 36.70 (200)
Ask (Size) 38.10 (200)
Prev. Close 34.18
Today's Range 34.57 - 38.04
52wk Range 14.62 - 49.70
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
September 28, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression ↗
September 24, 2026
Definium Therapeutics (NASDAQ:DFTX) Chief Medical Officer Dan Karlin said the company’s recent Phase III results for DT120 showed statistically significant improvements in generalized anxiety disorder,... 
Via MarketBeat

Performance

52-Week Range 25.8% below 52-week high
36.90
14.6252W Low 49.7052W High
1 Week 3.0% below 1-week high
32.841W Low 38.041W High

Definium Therapeutics, Inc. - Common Shares (DFTX) traded between $14.62 and $49.70 over the past 52 weeks and last traded at $36.90, 25.8% below its 52-week high. Over the past week it ranged between $32.84 and $38.04.

Past 12 Months
+1.8%
-2.2%
-15.5%
+65.8%
+139.9%
+139.9%
1W +$0.67
1M -$0.83
3M -$6.75
6M +$14.65
YTD +$21.52
1Y +$21.52

DFTX was +139.9% over the past year, +65.8% over six months, +139.9% year to date, +1.8% in the last week.

12 Months vs Market
DFTX
+139.9%
DIA
+13.5%
SPY
+19.2%
QQQ
+27.4%
IWM
+17.3%

Over the past 12 months DFTX returned +139.9% versus DIA (Dow) +13.5%, SPY (S&P 500) +19.2%, QQQ (Nasdaq 100) +27.4% and IWM (Russell 2000) +17.3%.

Volume & Liquidity 1.30× 3-mo avg
Today 2,773,835 3-mo avg 2.1M
1W
2.4M
1M
2.6M
3M
2.1M
6M
2.5M
YTD
2.3M
1Y
2.3M

DFTX most recently traded 2,773,835 shares against a 3-month average daily volume of 2.1M.

More News

Read More
News headline image
Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study ↗
September 19, 2026
Via MarketBeat
Definium Therapeutics (NASDAQ:DFTX) Slides After Q2 Loss Misses Estimates on Warrant Charge ↗
August 06, 2026
Via Chartmill
News headline image
Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
September 14, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
September 14, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
September 13, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
September 10, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
September 08, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
August 31, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
August 26, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
August 17, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics’ DT120 Meets Phase III Goals in GAD Study ↗
August 13, 2026
Via MarketBeat
Wondering what's happening in today's pre-market session? ↗
August 12, 2026
Via Chartmill
News headline image
Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
August 12, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Q2 Earnings Call Highlights ↗
August 06, 2026
Via MarketBeat
Topics Earnings
News headline image
Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
August 06, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
August 05, 2026
From USA News Group
Via GlobeNewswire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
August 03, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
July 30, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
July 20, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
July 16, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
July 14, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Definium Therapeutics Announces New Employee Inducement Grants
July 06, 2026
From Definium Therapeutics, Inc.
Via Business Wire
News headline image
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
June 30, 2026
Via FinancialNewsMedia

Frequently Asked Questions

Is Definium Therapeutics, Inc. - Common Shares publicly traded?
Yes, Definium Therapeutics, Inc. - Common Shares is publicly traded.
What exchange does Definium Therapeutics, Inc. - Common Shares trade on?
Definium Therapeutics, Inc. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Definium Therapeutics, Inc. - Common Shares?
The ticker symbol for Definium Therapeutics, Inc. - Common Shares is DFTX on the Nasdaq Stock Market
What is the current price of Definium Therapeutics, Inc. - Common Shares?
The current price of Definium Therapeutics, Inc. - Common Shares is 36.90
When was Definium Therapeutics, Inc. - Common Shares last traded?
The last trade of Definium Therapeutics, Inc. - Common Shares was at 10/09/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap